Use of the steroid derivative RPR 106541 in combination with site- directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 594-602

  Stevens, Jeffrey C ^a   Domanski, Tammy L ^b   Harlow, Greg R ^c   White, Rebecca B ^a,d   Orton, Edward ^a   Halpert, James R ^b  

^a Rhône Poulenc Rorer ^*  (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Selectide Corporation   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA,17ALPHA [BUTYLIDENEBIS(OXY)] 6ALPHA,9ALPHA DIFLUORO 11BETA HYDROXY 17BETA (METHYLTHIO)ANDROSTA 4 EN 3 ONE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; METHYL 16ALPHA,17ALPHA BUTYLIDENEBIS(OXY) 6ALPHA,9ALPHA DIFLUORO 11BETA,21 DIHYDROXY 3 OXOANDROSTA 1,4 DIENE 17BETA THIOCARBOXYLATE; PHENACETIN O DEETHYLASE; RPR 104065; RPR 106541; RPR 112020; RPR 112022; RPR 112023; RPR 112903; STEROID; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTEREOISOMER; DOG; DRUG METABOLISM; ENZYME ISOLATION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; RAT; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANDROSTENES; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFOXIDES;

EID: 0032765801     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Check WA and Kaliner MA (1990) Pharmacology and pharmacokinetics of topical corticosteroid derivatives used for asthma therapy. Am Rev Respir Dis 141 (2 Pt 2):S44-S51.
2. Domanski TL, Liu J, Harlow GR and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role of steroid hydroxylase activity and α-naphthoflavone stimulation. Arch Biochem Biophys 350:223-232.
3. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg JE, Lennard MS, Tucker GT and Wolf CR (1995) Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 270:29055-29058.
4. Ferenczy GG and Morris GM (1989) The active site of cytochrome P-450 nifedipine oxidase: A model-building study. J Mol Graph 7:206-211.
5. Flack HD (1989) On enantiomorph-polarity estimation. Acta Crystollogr. A 39:876-881.
6. Fleming CM, Branch RA, Wilkinson GR and Guengerich FP (1992) Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 41:975-980.
7. Fukuda T, Imai Y, Komori M, Nakamura M, Kusunose E, Satouchi K and Kusunose M (1993) Replacement of Thr-303 of P450 2E1 with serine modified the regioselectivity of its fatty acid hydroxylase activity. J Biochem 113:7-12.
8. Gillam EM, Baba T, Kim BR, Ohmori S and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305:123-131.
9. Gotoh O, (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
10. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
11. Guengerich FP (1995) Human Cytochrome P450 Enzymes, In Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed (Ortiz de Montellano PR, ed) pp 473-535, Plenum Press, New York.
12. Halpert JR and He Y-A (1993) Engineering of cytochrome P450 2B1 specificity. J Biol Chem 268:4453-4457.
13. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. J Biol Chem 272:5396-5402.
14. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci 95:6636-6641.
15. Hasler JA, Harlow GR, Szklarz GD, John GH, Kedzie KM, Burnett VL, He Y-A, Kaminsky LS and Halpert JR (1994) Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: Importance of amino acid residues 114, 290, and 363 in substrate specificity. Mol Pharmacol 46:338-345.
16. He Y-A, He Y-Q, Szklarz GD and Halpert JR (1997) Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry 36:8831-8839.
17. Heyn H, White RW and Stevens JC (1996) Catalytic role of cytochrome P450 2B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954.
18. Jonsson G, Astrom A and Andersson P (1995) Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 23:137-142.
19. Jounaidi Y, Hyrailles V, Gervot L and Maurel P (1996) Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein. Biochem Biophys Res Commun 221:466-470.
20. Korzekwa KR and Jones JP (1993) Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 3:1-18.
21. Koymans LM, Vermeulen NP, Baarslag A and Donne-Op den Kelder GM (1993) A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comput Aided Mol Design 7:281-289.
22. Kronbach T, Mathys D, Gut J, Catin T and Meyer U (1987) High-performance liquid chromatographic assays for bufuralol 1 'hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
23. Kumar GN, Walle UK and Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6-hydroxylation. J Pharmacol Exp Ther 268:1160-1165.
24. Leemann T, Transon C and Dayer P (1993) Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
25. Maenpaa J, Hall SD, Ring BJ, Strom SC and Wrighton SA (1998) Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
26. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
27. cam. Biochemistry 28: 917-922.
28. Schwab GE, Raucy JL and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol Pharmacol 33:493-499.
29. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
30. Szklarz GD and Halpert JR (1997) Molecular modeling of cytochrome P450 3A4. J Comput Aided Mol Design 11:265-272.
31. Szklarz GD, He YA and Halpert JR (1995) Site-directed mutagenesis as a tool for molecular modeling of cytochrome P450 2B1. Biochemistry 34:14312-14322.
32. Szklarz GD, Ornstein RL and Halpert JR (1994) Application of 3-dimensional homology modeling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results. J Biomol Struct Dyn 12:61-78.
33. Ueng Y-F, Kuwabara T, Yamazaki H and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
34. von Wachenfeldt C and Johnson EF (1995) Structures of Eukaryotic Cytochrome P450 Enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed (Ortiz de Montellano PR, ed) pp 183-223, Plenum Press, New York.
35. Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kahzubari FF, Larrey D and Guengerich FP (1983) Purification and characterization of six Cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22:5375-5383.
36. Wrighton SA, Ring BJ, Watkins PB and VandenBranden M (1989) Identification of a polymorphically expressed member of the human Cytochrome P-450III family. Mol Pharmacol 86:97-105.
37. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE and Cashman JR (1993) In vitro methods for assessing human hepatic drug metabolism: Their role in drug development. Drug Metab Rev 25:453-484.
38. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325:174-182.
39. Yamazaki H and Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161-169.